Hodgkin’s lymphoma after 2-month infliximab therapy: case report

Saeidi S., Ahmadzadeh A., Rajaei E., RAHIM F., Jazayeri S. N., Shahjahani M., ...More

Comparative Clinical Pathology, vol.24, no.4, pp.911-914, 2015 (Scopus) identifier

  • Publication Type: Article / Article
  • Volume: 24 Issue: 4
  • Publication Date: 2015
  • Doi Number: 10.1007/s00580-014-2007-6
  • Journal Name: Comparative Clinical Pathology
  • Journal Indexes: Scopus
  • Page Numbers: pp.911-914
  • Keywords: Ankylosing spondylitis, Hodgkin’s lymphoma, Infliximab, Rheumatoid arthritis, TNF-α
  • Kocaeli University Affiliated: Yes

Abstract

Ankylosing spondylitis (AS) is a chronic inflammatory disease mainly affecting the axial skeleton. Joint pain and stiffness as well as reduced spinal mobility are among the clinical symptoms of this disease. AS mostly affects younger males. TNF blocker drugs like infliximab are among the best treatments for AS, relieving many symptoms of the disease by neutralizing the effect of TNF. However, the use of these drugs may increase the risk of malignancies. In this research, a 23-year-old male with a history of AS was investigated, who was afflicted with Hodgkin’s lymphoma as a rare complication following infliximab administration.